Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMOR3-SV
2014-005079-10Phase 3Completed
- Sponsor
- Tokai Pharmaceuticals
- Start
- Apr 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of galeterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Tokai Pharmaceuticals. Primary endpoint: Radiographic progression-free survival. Started Apr 2015; status: completed.
02
Drugs
galeterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2014-005079-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005079-10.